MiRNA-610 acts as a tumour suppressor to depress the cisplatin resistance in hepatocellular carcinoma through targeted silencing of hepatoma-derived growth factor

Abstract

Introduction: Hepatic malignancy is one of the most common malignant neoplasms around the globe, and hepatocellular carcinoma (HCC) is the most common type. In this study, the roles and mechanisms of MiRNA-610 in the chemo resistance of HCC will be discussed. Material and methods: The expression of MiRNA-610 and hepatoma-derived growth factor (HDGF) in HCC tissues and cell line was detected by quantitative real-time PCR. The proliferation and chemo resistance were analysed by MTT assay. Flow cytometry was used to examine the apoptosis rate. Luciferase reporter assay was used to verify the correlation between MiRNA-610 and HDGF. HDGF protein expression was detected by Western blot. Results: Our study confirmed the low-expression of MiRNA-610 in HCC tissues and cell line. Its low expression was related to high T stages and poor differentiation of HCC, and was a prognostic factor for HCC. MiRNA-610 upregulation inhibited cell proliferation and induced apoptosis of HepG2 cells. MiRNA-610 enhancement decreased the half maximal inhibitory concentration for cisplatin (DDP) and depressed the DDP resistance in HepG2 cells. The specific correlation between MiRNA-610 and HDGF was tested by luciferase reporter assay and western blot. The transfection with HDGF expression vector up-regulated the expression of HDGF protein silenced by MiRNA-610 enhancement. HDGF overexpression was found to reverse partly the regulatory roles of MiRNA-610 on malignancy and DDP resistance. Conclusions: MiRNA-610 not only played a tumour suppressor role in HCC but also affected chemo resistance to DDP. This role is mainly mediated through targeted silencing of the HDGF gene, which may offer a new potential therapeutic target and improve the clinical therapeutic effect for HCC.

MicroRNA miR-212-3p targets NFIA to suppress HBV replication and tumor progression in hepatocellular carcinoma via repressing Enhancer I activity

“…HBV infection is considered as a central reason for hepatocarcinogenesis. It is well known that host miRNAs are implicated in virus infection and replication [7,19].…”

“…MiRNAs have been demonstrated to be involved in kinds of physiological or pathological changes in human diseases [7]. Convincing evidence shows the association between host miRNAs and virus infection [8].…”

The interplay between noncoding RNAs and drug resistance in hepatocellular carcinoma: the big impact of little things

“…This sheds light on how miR-9 regulates HCC chemosensitivity and provides a potential target for enhancing the effectiveness of HCC chemotherapy [ 79 ]. Apart from its role as a tumor suppressor in HCC, miR-610 also affects the resistance of HCC cells to cisplatin by specifically silencing the HDGF gene [ 80 ]. Conversely, the targeting of FASLG by miR-21-5p decreased the sensitivity of HCC to cisplatin treatment [ 81 ].…”

MiRNA-296-5p promotes the sensitivity of nasopharyngeal carcinoma cells to cisplatin via targeted inhibition of STAT3/KLF4 signaling axis

“…For example, Wuerkenbieke et al demonstrated that miRNA-150 downregulation contributed to the pertuzumab resistance in ovarian cancer via activating PI3K-Akt pathway 6 . Recently, Xu et al found that miRNA-610 could affect chemoresistance to DDP in hepatocellular carcinoma through targeted silencing of the HDGF gene 7 . Moreover, miRNA-375-3p could enhance 5-fluorouracil chemosensitivity in colorectal cancer by targeting thymidylate synthase 8 .…”